EUVIMEDEUVIMED entdecken
Fallbericht

A Novel BAFF / APRIL Dual Inhibitor in Treating Refractory Autoimmune Hepatitis

Tianyu Mao, Xiong Ma, Xiao Xiao iD

Liver International · 2026

DOI: 10.1111/liv.70488 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Liver International, 2026. Verfasst von Tianyu Mao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogene…. Hauptthemen laut MEDLINE: Hepatitis, Autoimmune, B-Cell Activating Factor, Immunosuppressive Agents, Tumor Necrosis Factor Ligand Superfamily Member 13. Die Arbeit nennt 14 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A subset of autoimmune hepatitis (AIH) patients fail to respond to standard treatments or experience frequent relapses. This study evaluates the efficacy and safety of telitacicept, a BAFF/APRIL dual inhibitor, as a rescue therapy. Two AIH patients treated with telitacicept were included. The first, steroid‐dependent and refractory to multiple immunosuppressants, showed significant reductions in transaminases and immunoglobulin G, enabling steroid tapering. The second, with comorbid systemic lupus erythematosus, maintained remission and reduced steroid and mycophenolate mofetil doses. No severe adverse events were reported. Telitacicept shows promise as a safe therapy for refractory AIH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis, AutoimmuneB-Cell Activating FactorImmunosuppressive AgentsTumor Necrosis Factor Ligand Superfamily Member 13HumansFemaleAdultMiddle AgedTreatment OutcomeMaleLupus Erythematosus, SystemicMycophenolic AcidDrug Therapy, Combination

Stichwörter der Autor:innen

autoimmune hepatitiscomplete biochemical responserefractorytelitacicept

Substanzen

B-Cell Activating FactorImmunosuppressive AgentsTumor Necrosis Factor Ligand Superfamily Member 13TNFSF13B protein, humanMycophenolic Acid

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao…

ORCID-Profile: Xiao Xiao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Mao, T., Ma, X., & Xiao, X. (2026). A Novel BAFF / APRIL Dual Inhibitor in Treating Refractory Autoimmune Hepatitis. Liver International. https://doi.org/10.1111/liv.70488

Vancouver

Mao T, Ma X, Xiao X. A Novel BAFF / APRIL Dual Inhibitor in Treating Refractory Autoimmune Hepatitis. Liver International. 2026. doi:10.1111/liv.70488

BibTeX
@article{Mao2026,
  author = {Mao, Tianyu and Ma, Xiong and Xiao, Xiao},
  title = {A Novel BAFF / APRIL Dual Inhibitor in Treating Refractory Autoimmune Hepatitis},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70488}
}
Kostenlos starten →